Professionals 258 results
Capabilities 52 results
Practice Area
Bankruptcy Litigation & Investigations
Practice Area
Practice Area
Government Program Fraud, False Claims Act & Qui Tam Litigation
Experience 54 results
Experience
|January 9, 2025
Delaware Court Sees Though Plaintiffs’ Poorly Disguised Derivative Claims
Experience
|December 19, 2024
Winston & Strawn Represents Estrella Immunopharma in US$100 Million Shelf Registration
Experience
|December 12, 2024
Winston advises Crystal on its acquisition of Armonial Partners
Insights & News 1,884 results
Client Alert
|May 20, 2025
|3 Min Read
Private Credit Is Booming; Banks Want Back In
Competition Corner
|May 16, 2025
|7 Min Read
In a marked shift toward competition-focused healthcare policy, the latest Executive Order on drug pricing reflects the Administration’s expanding use of antitrust tools to address high pharmaceutical costs. Framed around the “most-favored-nation” principle, this initiative is more than a pricing measure—it signals a broader regulatory agenda that targets market power and pricing disparities long shielded from traditional enforcement. Here’s what companies across the healthcare sector need to know.
Client Alert
|May 16, 2025
|3 Min Read
CFPB Plans to Close Repeat Offender Registry
Other Results 56 results
Site Content
What Is Prospectus Delivery for an IPO?
Site Content
Site Content